TCON - TRACON highlights updated envafolimab clinical results in MSI-H/dMMR colorectal cancer

TRACON Pharmaceuticals ([[TCON]] -13.3%) highlighted updated clinical data from the pivotal trial of envafolimab in MSI-H/dMMR cancer patients that were presented by the corporate partners, 3D Medicines and Alphamab Oncology. Duration of response was ?12 months in 75% of patients and overall survival was ?12 months in 65% of patients.The ORR in the overall population was 43%, DOR was ?12 months in 92% of patients and OS was ?12 months in 75% of patients.Envafolimab demonstrated good tolerability and safety and there continued to be no infusion-related reactions.The trial enrolled 103 patients with MSI-H CRC, GC or with dMMR in other advanced solid tumors at clinical sites in China.Shares down 13.3%.

For further details see:

TRACON highlights updated envafolimab clinical results in MSI-H/dMMR colorectal cancer